{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:37:25Z","timestamp":1760315845336,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jjcc.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T07:05:57Z","timestamp":1658559957000},"page":"487-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism"],"prefix":"10.1016","volume":"80","author":[{"given":"Seiichi","family":"Hiramori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Oi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Toyofuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriaki","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syunsuke","family":"Saga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Sasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyonori","family":"Togi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2022.07.001_bb0005","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0010","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0015","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1183\/09031936.00194213","article-title":"Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011","volume":"44","author":"De Miguel-Diez","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0020","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","article-title":"Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany","volume":"41","author":"Keller","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1160\/th15-02-0172","article-title":"Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in northwestern Italy","volume":"115","author":"Dentali","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1160\/TH17-08-0531","article-title":"Acute pulmonary embolism in a national danish cohort: increasing incidence and decreasing mortality","volume":"118","author":"Lehnert","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1253\/circj.CJ-08-0372","article-title":"Venous thromboembolism","volume":"73","author":"Sakuma","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0040","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM197910183011602","article-title":"Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis","volume":"301","author":"Hull","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0045","first-page":"80","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study","volume":"50","author":"Liakishev","year":"2010","journal-title":"Kardiologiia"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0050","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Scott","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0055","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Bailey","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0065","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0075","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0085","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0090","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: american College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0095","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0105","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1253\/circj.CJ-88-0010","article-title":"Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009)","volume":"75","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0110","first-page":"789","article-title":"Stroke prevention in atrial fibrillation: an asian perspective","volume":"111","author":"Chiang","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0115","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world: from the COMMAND VTE registry","volume":"82","author":"Yamashita","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0125","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.amjcard.2012.08.014","article-title":"Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from affirm)","volume":"110","author":"Sullivan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2004.05348.x","article-title":"Individual time within target range in patients treated with vitamin K antagonists: Main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism","volume":"128","author":"Veeger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0140","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013)","volume":"78","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0155","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1538-7836.2011.04443.x","article-title":"Racial differences in venous thromboembolism","volume":"9","author":"Zakai","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0160","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0049-3848(09)70136-7","article-title":"Effects of race and ethnicity on the incidence of venous thromboembolism","volume":"123","author":"White","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0165","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.06.004","article-title":"Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: a meta-analysis of randomized trials","volume":"244","author":"Carmo","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jjcc.2014.07.013","article-title":"Warfarin anticoagulation intensity in japanese nonvalvular atrial fibrillation patients: a J-RHYTHM registry analysis","volume":"65","author":"Yamashita","year":"2015","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2022.07.001_bb0180","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1253\/circj.CJ-18-0587","article-title":"Time in therapeutic range and disease outcomes in elderly japanese patients with nonvalvular atrial fibrillation","volume":"82","author":"Inoue","year":"2018","journal-title":"Circ J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:06:49Z","timestamp":1760274409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508722001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0914508722001630"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.07.001","relation":{},"ISSN":["0914-5087"],"issn-type":[{"type":"print","value":"0914-5087"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}